Eliquis Offered to Cash-Paying Patients at More Than 40% Discount to Current List Price, Sotyktu at More Than 80% Discount to Current List Price PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb ...

BMS Foundation launches national programme to bolster mental health diversion initiatives: Lawrenceville, New Jersey Saturday, January 17, 2026, 12:00 Hrs [IST] The Bristol Myers ...

Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview Bristol-Myers Squibb ...

Cellares to provide proof-of-concept manufacturing for a key BMS CAR-T cell therapy Cellares' proprietary Cell Shuttle is a cost-efficient, reliable, fully automated, and highly scalable manufacturing ...

Eliquis 360 Support Program Now Offers Eliquis to Cash-Paying Patients at More than 40% Discount to Current List Price PRINCETON, N.J.--(BUSINESS WIRE)-- The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY ...

Cash management is critical for pharmaceutical companies: The ability to fund drug innovation can make the difference between ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

Bristol-Myers Squibb Co (NYSE:BMY) filed a lawsuit on Tuesday against the U.S. Health Resources and Services Administration (HRSA) and the U.S. Department of Health and Human Services (HHS), alleging ...

-- Bristol Myers Squibb exercises an exclusive license option for ArsenalBio’s AB-4000 series programs-- -- ArsenalBio is eligible for additional milestone payments and royalties as the programs ...

Could the pharmaceutical giant turn things around next year? Let's find out whether Bristol Myers Squibb is a buy, sell, or hold heading into 2026.